Vinay Gupta, MD
Hematology & Oncology · Saint Joseph, MONPI 1629224357
Payments from drug & device makers
Across 261 payments — averaging $320.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$31K
- Mckesson Corporation$25K
- Merck$19K
- GSK$3K
- Novartis$2K
- AstraZeneca$740
- plus $3K from 32 others
What the payments were for
- Consulting fees$4,73014%
- Speaking & faculty fees$25,00073%
- Food & beverage$4,64613%
- Education$980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 6 | $30,584 |
| Mckesson Corporation | 1 | $25,000 |
| Merck | 21 | $18,923 |
| GSK | 14 | $2,989 |
| Novartis | 18 | $2,265 |
| AstraZeneca | 37 | $740 |
| AbbVie | 23 | $510 |
| Pfizer | 25 | $392 |
| Gilead | 22 | $351 |
| Sanofi | 7 | $243 |
| Genentech USA, Inc. | 10 | $190 |
| Daiichi Sankyo Inc. | 6 | $122 |
| Regeneron Healthcare Solutions, Inc. | 6 | $121 |
| Array Biopharma Inc | 6 | $119 |
| Incyte Corporation | 5 | $101 |
| E.r. Squibb & Sons, L.L.C. | 6 | $98 |
| Astellas Pharma US Inc | 5 | $95 |
| Sobi, Inc | 4 | $91 |
| Bristol Myers Squibb | 6 | $90 |
| Eisai Inc. | 4 | $68 |
| Exelixis Inc. | 3 | $52 |
| Stemline Therapeutics Inc. | 3 | $52 |
| Recordati_rare_diseases_inc. | 2 | $46 |
| AVEO Pharmaceuticals, Inc. | 3 | $45 |
| Johnson & Johnson | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Rigel Pharmaceuticals, Inc. | 2 | $38 |
| Servier Pharmaceuticals LLC | 2 | $35 |
| Caris MPI, Inc. | 1 | $27 |
| Legend Biotech USA Inc. | 1 | $27 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Medtronic | 1 | $21 |
| Tempus AI, Inc | 1 | $20 |
| Geron Corporation | 1 | $19 |
| Bayer | 1 | $18 |
| Tersera Therapeutics LLC | 1 | $17 |
| Iovance Biotherapeutics, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$83,641 in reported general payments places this provider in the 80th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 26 | $433,700 |
| CalquenceAcalabrutinib Maleate | 25 | $380,104 |
| JaypircaPirtobrutinib | 15 | $330,331 |
| RevlimidLenalidomide | 13 | $188,917 |
| XtandiEnzalutamide | 13 | $156,408 |
| XareltoRivaroxaban | 46 | $38,820 |
| EliquisApixaban | 42 | $32,450 |
| CreonLipase/Protease/Amylase | 11 | $9,448 |
| Anastrozole | 116 | $1,854 |
| Imatinib Mesylate | 12 | $1,812 |
| Letrozole | 49 | $1,389 |
| Potassium Chloride | 64 | $1,287 |
| Exemestane | 12 | $967 |
| Dexamethasone | 38 | $846 |
| Prochlorperazine Maleate | 88 | $843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $740 | $380,10425 claims |
| Lilly USA, LLCJaypirca | $15 | $330,33115 claims |
| Bristol Myers SquibbRevlimid | $90 | $188,91713 claims |
| Astellas Pharma US IncXtandi | $95 | $156,40813 claims |
| Johnson & JohnsonXarelto | $40 | $38,82046 claims |
| PfizerEliquis | $392 | $32,45042 claims |
| AbbVieCreon | $510 | $9,44811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Saint Joseph
- Gopichand PendurtiSaint Joseph$141K
- Stephanie GraffKansas City$6.2M
- Suman KambhampatiKansas City$4.9M
- Geoffrey UySaint Louis$4.1M
- Jaswinder SinghKansas City$3.9M
- Mark FeslerSaint Louis$2M
- James MosleyCape Girardeau$1.7M
- Shahzad RazaKansas City$1.7M
- Gerhard HildebrandtColumbia$1.6M
- David SchlossmanColumbia$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.